|
|
Article: LifeSpan BioSciences Announces Agreement With Pfizer for Expanded DrugTarget(TM) Localization Database.
- Article from:
- Business Wire
- Article date:
- December 21, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SEATTLE -- LifeSpan BioSciences, Inc., a leading proteomics company specializing in molecular pathology, today announced a multi-year agreement with Pfizer Inc. (NYSE:PFE).
Under the terms of the agreement, Pfizer will gain access to all the features of the DrugTarget Database(TM), including informatics on more than 3200 genes, 852 comprehensive immunohistochemistry (IHC) reports with localization information on more than 400 potential drug targets selected by pharmaceutical company subscribers, and innovative search and sort tools. In addition, Pfizer will nominate at least 60 new targets to be studied by IHC and published in the consortium database. LifeSpan ...
Related newspaper, magazine, and journal articles:
|
|
Article: LifeSpan BioSciences Multimillion-Dollar Financing, ...
PR Newswire;
March 31, 1997 ;
700+ words
... ... SEATTLE, March 31 /PRNewswire/ -- LifeSpan BioSciences, Inc., an early-stage genomics ... experience in molecular biology. LifeSpan BioSciences, Inc., based in Seattle, Wash ... targets for drug discovery. SOURCE LifeSpan BioSciences Inc. -0- 03/31/97 /CONTACT ...
|
|